Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q3 FY24 results · Oct–Dec 2023
Astec LifeSciences reported revenue from operations of ₹50.79 crore (down 56.7% from Q3 FY23) and net loss of ₹24.33 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 50.79 | 117.18 | −56.7% | 110.79 | −54.2% |
| Other income | 0.91 | 3.79 | −76.0% | 0.98 | −7.1% |
| Total income | 51.70 | 120.97 | −57.3% | 111.77 | −53.7% |
| Profit before tax | (32.22) | 1.24 | Turned loss | (17.60) | Loss widened |
| Net profit for the period | (24.33) | 0.85 | Turned loss | (13.42) | Loss widened |
| Attributable to shareholders of the company | (24.33) | 0.84 | Turned loss | (13.43) | Loss widened |
| EPS, basic (₹) | (12.41) | 0.43 | Turned loss | (6.85) | Loss widened |
| Net margin (%) | -47.9 | 0.7 | -12.1 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 50.79 | 117.18 | −56.7% | 110.79 | −54.2% |
| Other income | 0.90 | 3.78 | −76.2% | 0.96 | −5.8% |
| Total income | 51.69 | 120.96 | −57.3% | 111.74 | −53.7% |
| Profit before tax | (32.25) | 1.21 | Turned loss | (17.64) | Loss widened |
| Net profit for the period | (24.35) | 0.83 | Turned loss | (13.45) | Loss widened |
| EPS, basic (₹) | (12.42) | 0.42 | Turned loss | (6.86) | Loss widened |
| Net margin (%) | -47.9 | 0.7 | -12.1 |
Consolidated
- Filed with BSE
- 05 Feb 2024, 15:42 IST
- Board meeting
- 25 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Feb 2024, 15:42 IST
- Board meeting
- 25 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE